This brand name is authorized in Austria, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Italy, Japan, Lithuania, Poland, United Kingdom, South Africa
The drug ZEVALIN contains one active pharmaceutical ingredient (API):
|
1
Ibritumomab tiuxetan (⁹⁰Y)
UNII 4Q52C550XK - IBRITUMOMAB TIUXETAN
|
|
Ibritumomab tiuxetan (⁹⁰Y) is a recombinant murine IgG1 kappa monoclonal antibody specific for the B-cell antigen CD20. Ibritumomab tiuxetan targets the antigen CD20 which is located on the surface of malignant and normal B-lymphocytes. During B-cell maturation, CD20 is first expressed in the midstage of B-lymphoblast (pre-B-cell), and is lost during the final stage of B-cell maturation to plasma cells. It is not shed from the cell surface and does not internalise on antibody binding. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZEVALIN Kit for radiopharmaceutical preparations for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01XC | † Monoclonal antibodies | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents |
| V10XX02 | Ibritumomab tiuxetan [90Y] | V Various → V10 Therapeutic radiopharmaceuticals → V10X Other therapeutic radiopharmaceuticals → V10XX Various therapeutic radiopharmaceuticals |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1208203, 1811236 |
| Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 03264001 |
| Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 015623 |
| Country: FR | Base de données publique des médicaments | Identifier(s): 66364008 |
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 397977 |
| Country: HK | Department of Health Drug Office | Identifier(s): 54925 |
| Country: IT | Agenzia del Farmaco | Identifier(s): 036311013 |
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 4291414G1020, 4300450G1027 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1031487 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100126554 |
| Country: ZA | Health Products Regulatory Authority | Identifier(s): A39/35/0016 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
